CAM
CMMB

Cormorant Asset Management’s Chemomab Therapeutics CMMB Stock Holding History

Cormorant Asset Management’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-72,042
Closed -$458K – 66
2023
Q1 		$458K Hold
72,042
– – 0.03% 69
2022
Q4 		$922K Hold
72,042
– – 0.06% 65
2022
Q3 		$718K Hold
72,042
– – 0.05% 67
2022
Q2 		$1.07M Hold
72,042
– – 0.08% 70
2022
Q1 		$1.38M Buy
+72,042
New +$1.42M 0.11% 71

Other funds holding CMMB

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $8.83B AUM 38.5% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $808M AUM 51.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cormorant Asset Management's CMMB Position: Q2 2023 in Review

Cormorant Asset Management sold out of Chemomab Therapeutics (CMMB) in Q2 2023, closing a stake of 72,042 shares — an estimated $458K sold.

Cormorant Asset Management first reported a position in CMMB in Q1 2022 and held it in 5 quarters. The position peaked at $1.38M in Q1 2022. 12 funds tracked by Wall St. Rank hold CMMB as of Q2 2023.

  • Cormorant Asset Management reported no remaining Chemomab Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Cormorant Asset Management sold 72,042 Chemomab Therapeutics shares in Q2 2023, an estimated $458K.
  • Cormorant Asset Management first reported a position in Chemomab Therapeutics in Q1 2022 and held it in 5 quarters.
  • Cormorant Asset Management's Chemomab Therapeutics position peaked at $1.38M in Q1 2022.
  • 12 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q2 2023.

Based on Cormorant Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.